- 期刊
- OpenAccess
Multimodal Analgesia of Nalbuphine Sebacate With Patient-Controlled Epidural Analgesia for Postcesarean Pain-A Retrospective Pilot Study
摘要
Background: Nalbuphine sebacate (Naldebain®), an intramuscular prodrug of nalbuphine, offers long-acting relief for postoperative pain. This study evaluates the efficacy and safety of Naldebain® for acute pain management postelective cesarean delivery. Methods: A retrospective review was conducted on 30 parturients who received epidural anesthesia for elective cesarean delivery. Group C (n = 20) received patient-controlled epidural analgesia (PCEA) alone, while Group N (n = 10) was administered a single 150 mg intramuscular dose of Naldebain® alongside PCEA. Postoperative pain intensity was assessed using the numeric rating scale at various intervals, with analgesic consumption, muscle tone, side effects, and patient satisfaction also recorded and analyzed. Results: Group N exhibited a significant reduction in PCEA fentanyl consumption on the first day compared to Group C (52.9 ± 18.7 vs. 70.8 ± 23.7 mcg, P = 0.045). Pain intensity did not significantly differ between the groups over three days postsurgery. Both groups were comparable regarding muscle tone, side effects, and overall satisfaction although fewer patients in Group N required rescue pain control (20% vs. 60%, P = 0.038). Conclusion: The combination of a single-dose Naldebain® with PCEA showed a fentanyl-sparing effect on the first postoperative day and decreased the need for rescue analgesics during PCEA without an increase in adverse events.